Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Targeted BRAF and MEK inhibition has become an appropriate first-line treatment of BRAF-mutant advanced cutaneous melanoma.
|
31753111 |
2020 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
|
31464610 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
As the current knowledge about pathogenesis, clinical and genetic features of cutaneous melanoma is not very clear, we aim to use bioinformatics to identify the potential key genes involved in the expression and mutation status of BRAF.
|
30925905 |
2019 |
Cutaneous Melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, the CM energetic demand mainly depends on glycolysis, whose upregulation is strictly linked to constitutive activation of BRAF/MAPK pathway affected by BRAF<sup>V600E</sup> kinase mutant.
|
31362075 |
2019 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma.
|
28485171 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM).
|
31200439 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance.
|
30681641 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis.
|
30997532 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a <i>BRAF<sup>V600E</sup></i> mutation.
|
31416844 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (<i>BRAF)</i> and neuroblastoma RAS viral oncogene homolog (<i>NRAS)</i> mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with <i>BRAF</i> and <i>NRAS</i> mutations.
|
31398831 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
|
31391014 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population.
|
31514399 |
2019 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy.
|
30959471 |
2019 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF is the most frequently mutated gene in skin melanoma.
|
30347273 |
2018 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To identify the dermoscopic features associated with BRAF mutation in cutaneous melanoma and to evaluate a model capable of predicting BRAF mutations on the basis of dermoscopic and clinicopathologic features that are easily accessible in normal clinical practice.
|
29307636 |
2018 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors have demonstrated significant survival benefits for patients with cutaneous melanoma.
|
30205280 |
2018 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e.g., BRAF as in cutaneous melanoma.
|
29433557 |
2018 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Compared to CM, which showed frequent mutations in known driver genes (BRAF 50.0%, NRAS 29.2%), MM displayed lower mutation frequencies (BRAF; 12.2%, p < 0.001, NRAS; 17.1%), and was significantly more enriched for triple wild-type (no mutations in BRAF, RAS, or NF1, 70.7% vs 25.0%, p < 0.001), IGF2R mutation (31.7% vs 6.3%, p = 0.002), and KIT mutation (9.8% vs 0%, p = 0.042).
|
30373548 |
2018 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to determine whether ABCB5 is highly expressed in BRAF inhibitor-resistant melanoma cells and to evaluate whether ABCB5 is involved in the development of resistance to BRAF inhibitors in cutaneous melanoma.
|
29929490 |
2018 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In cutaneous malignant melanoma, combined treatment with BRAF and MEK inhibitors is associated with high response rates and has been shown to improve progression free as well as overall survival compared to BRAF inhibition alone.
|
27641727 |
2017 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
|
29310328 |
2017 |
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status.
|
27790766 |
2017 |
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The study population comprised 83 patients with advanced cutaneous melanoma presenting with BRAF V600 mutation.
|
29084636 |
2017 |